The Safety and Clinical Efficacy of Dasatinib Plus Human CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Subjects With Ph-positive Acute Lymphoblastic Leukemia
To evaluate the safety and efficacy of Dasatinib plus CD19/CD22 Bispecific CAR-T for the treatment of elderly Ph-positive lymphoblastic leukemia. Newly diagnosed Ph-positive patients will be given Dasatinib plus VP chemotherapy for induction treatment,if a hematologic complete remission was observed then a lymphocyte collection will be administrated to patients. Then chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19/CD22 CAR+ T cells
• (1)55 to 70 Years Old, Male and female;
• (2) Newly diagnosed Ph-positive ALL
• (3) ECOG score 0-1;
• (4) The venous access required for collection can be established and mononuclear cell collection can be determined by the investigators;
• (5) Liver, kidney and cardiopulmonary functions meet the following requirements:
‣ Creatinine is in the normal range;
⁃ Left ventricular ejection fraction \>50%;
⁃ Baseline oxygen saturation\>92%;
⁃ Total bilirubin ≤ 1.5×ULN;
⁃ ALT and AST ≤ 2.5×ULN;
• (6) Able to understand and sign the Informed Consent Document